Amedisys (NASDAQ:AMED) Price Target Cut to $125.00

Amedisys (NASDAQ:AMEDGet Rating) had its target price reduced by Stephens from $155.00 to $125.00 in a research note released on Tuesday morning, The Fly reports. They currently have an equal weight rating on the health services provider’s stock.

Other research analysts have also issued research reports about the company. UBS Group raised Amedisys from a sell rating to a neutral rating and upped their price target for the company from $152.00 to $168.00 in a research report on Tuesday, March 1st. Truist Financial reduced their target price on Amedisys from $210.00 to $200.00 and set a buy rating on the stock in a report on Friday, February 25th. SVB Leerink reduced their target price on Amedisys from $131.00 to $117.00 and set a market perform rating on the stock in a report on Friday, May 27th. StockNews.com assumed coverage on Amedisys in a report on Thursday, March 31st. They set a hold rating on the stock. Finally, Credit Suisse Group reduced their target price on Amedisys from $200.00 to $195.00 and set an outperform rating on the stock in a report on Friday, February 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amedisys has an average rating of Moderate Buy and a consensus price target of $173.27.

NASDAQ AMED opened at $115.28 on Tuesday. Amedisys has a 1-year low of $101.61 and a 1-year high of $276.21. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42. The stock has a 50-day moving average of $122.52 and a 200-day moving average of $142.33. The firm has a market cap of $3.76 billion, a PE ratio of 19.84, a price-to-earnings-growth ratio of 2.10 and a beta of 0.89.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.12. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. The company had revenue of $545.26 million during the quarter, compared to analyst estimates of $557.81 million. During the same quarter in the previous year, the company posted $1.54 EPS. As a group, equities research analysts forecast that Amedisys will post 5.29 earnings per share for the current fiscal year.

In other news, insider David L. Kemmerly sold 2,500 shares of the stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the transaction, the insider now directly owns 16,336 shares of the company’s stock, valued at approximately $2,896,536.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Amedisys by 55.3% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock valued at $38,000 after buying an additional 83 shares during the period. Prudential Financial Inc. raised its holdings in Amedisys by 2.5% in the 1st quarter. Prudential Financial Inc. now owns 3,728 shares of the health services provider’s stock worth $643,000 after purchasing an additional 90 shares during the period. Van ECK Associates Corp raised its holdings in Amedisys by 13.6% in the 4th quarter. Van ECK Associates Corp now owns 775 shares of the health services provider’s stock worth $125,000 after purchasing an additional 93 shares during the period. Truist Financial Corp raised its holdings in Amedisys by 3.6% in the 1st quarter. Truist Financial Corp now owns 2,698 shares of the health services provider’s stock worth $465,000 after purchasing an additional 93 shares during the period. Finally, Louisiana State Employees Retirement System raised its holdings in Amedisys by 1.2% in the 4th quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the health services provider’s stock worth $1,360,000 after purchasing an additional 100 shares during the period. 90.47% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.